Brief: Hyloris Announces FDA Acceptance Of New Drug Application For Maxigesic® IV In Post-Operative Pain

Hyloris Pharmaceuticals SA

01/11/2021 06:07

Nov 1 (Reuters) - Hyloris Pharmaceuticals SA  HYL.BR :
    * HYLORIS ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION
FOR
MAXIGESIC® IV IN POST-OPERATIVE PAIN
    * HYLORIS TO RECEIVE $1 MILLION MILESTONE PAYMENT
    * MAXIGESIC® IV HAS POTENTIAL TO COMBAT OPIOID CRISIS IN
U.S.
    * PATENTS ARE EXPECTED TO BE ISSUED EARLY 2022 AFTER
COMPLETION OF
FINAL ADMINISTRATIVE REQUIREMENTS
    * PDUFA DATE WILL BE NOTIFIED LATER THIS YEAR AND IS
ESTIMATED TO
BE BETWEEN AUGUST AND SEPTEMBER 2022

Source text for Eikon:  ID:nGNEc0SX15 
Further company coverage:  HYL.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))